Truist Financial Corp Has $34.45 Million Position in Gilead Sciences, Inc. $GILD

Truist Financial Corp reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 310,337 shares of the biopharmaceutical company’s stock after selling 42,786 shares during the period. Truist Financial Corp’s holdings in Gilead Sciences were worth $34,447,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth $215,000. Sivia Capital Partners LLC lifted its stake in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares during the last quarter. Cooper Financial Group boosted its holdings in shares of Gilead Sciences by 11.1% during the 2nd quarter. Cooper Financial Group now owns 2,603 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 261 shares in the last quarter. Finally, Bartlett & CO. Wealth Management LLC grew its position in Gilead Sciences by 5.2% during the 2nd quarter. Bartlett & CO. Wealth Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $873,000 after acquiring an additional 392 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on GILD. Royal Bank Of Canada lifted their price target on Gilead Sciences from $100.00 to $103.00 and gave the company a “sector perform” rating in a research note on Tuesday, January 20th. Needham & Company LLC lifted their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Scotiabank began coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target for the company. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Finally, Mizuho increased their price objective on Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $135.56.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the chief financial officer directly owned 150,503 shares in the company, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the sale, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 257,397 shares of company stock worth $33,385,512 over the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wolfe Research raised its price target to $155 (from $150) and kept an “outperform” rating — implying ~10% upside from current levels. Wolfe Research PT Raise
• Positive Sentiment: Citigroup published a bullish forecast for strong price appreciation, supporting demand expectations for GILD. Citigroup Forecast
• Positive Sentiment: Truist Financial also issued a forecast calling for meaningful upside, lining up with broader analyst optimism. Truist Forecast
• Positive Sentiment: BMO Capital Markets added to the chorus of bullish forecasts, which reinforces analyst-driven buying interest. BMO Forecast
• Positive Sentiment: UBS reiterated expectations for upside, further supporting consensus that GILD’s fundamentals and pipeline justify higher valuations. UBS Note
• Positive Sentiment: Coverage pieces (BarChart, Zacks interest) note that Gilead has outperformed the market and that analysts are broadly optimistic — positive sentiment that can attract momentum flows. BarChart Analysts Overview
• Neutral Sentiment: Zacks flagged increased investor attention to GILD (tracking user searches), which can boost volume but is not a directional catalyst by itself. Zacks Attention Note
• Neutral Sentiment: Reported short-interest data is inconsistent (entries show increases but list 0 shares / NaN), suggesting a data glitch — no clear short-squeeze or heavy shorting signal from this report.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares at ~$139.89 (?$1.4M), trimming his holding ~1.76%. Insider sales can be read negatively by some investors even if part of routine diversification. SEC Form 4

Gilead Sciences Trading Down 0.1%

GILD opened at $139.55 on Friday. The company has a fifty day moving average price of $125.05 and a two-hundred day moving average price of $119.38. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $141.71. The company has a market cap of $173.14 billion, a P/E ratio of 21.64, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.